News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Transition Therapeutics Inc. Appoints Andre Uddin B.Sc., Ph.D. As Vice-President Of Strategic Development
September 12, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TORONTO, Sept. 12 /CNW/ - Transition Therapeutics Inc. ("Transition") (TSX: TTH), is pleased to announce the appointment of Dr. Andre Uddin as Vice-President of Strategic Development.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
IPO tracker
Generate’s IPO Could Reach $425M, Largest Raise Yet
February 24, 2026
·
5 min read
·
Tristan Manalac
Manufacturing
AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois
February 24, 2026
·
2 min read
·
Nick Paul Taylor
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
February 24, 2026
·
3 min read
·
Annalee Armstrong
